Clinical Observation On Yiqihuoxue Huatantongluo In The Treatment Of Pulmonary Interstitial Fibrosis

Objective:Through investigate the therapeutic effects of the method of Yiqihuoxue huatantongluo on pulmonary interstitial fibrosis, and thus provid the new clinical basis on the prevention of pulmonary interstitial fibrosis.Methods:36patients met the diagnostic criteria of pulmonary interstitial fibrosis, were treated with a prescription of Yiqihuoxue huatantongluo (basic drugs:Astragalus,Codonopsis, Atractylodes, Adenophora, Ganoderma lucidum, Morus alba, bai qian, Coltsfoot, perilla seed, radish seed, Salvia, peach kernel, safflower, leeches, Curcuma, Citrus aurantium, woody, tangerine peel) orally treatment, clinical addition and subtraction. two times to take one dosage per day,150ml of each dosage, the period of treatment is3months. I analysis the changes of the total effect, TCM symptom score, lung function, Chest Imaging, Sa02while patients in the6minutes walking test, as well as the quality of life by the paired t-test, in order to evaluate the therapeutic effects of the method of Yiqihuoxue huatantongluo on pulmonary interstitial fibrosis.Result: 1.In the overall clinical efficacy evaluation,36patients, which improve the8cases, stable in25cases, aggravated3cases, the total efficiency (improved+stable rate) is91.66%.2. In the evaluation of TCM symptom score, comparing the scores before and after treatment, found that the difference is statisti-cally significant (P<0.05)3. In the evaluation of the efficacy of lung function,by paired t-test, found that after three months of medical intervention, the patients have a great change in the FVC、DLco and Pa02, comparing with the deta of pre-treatment,the difference is statistically significant (P<0.05)4. In the evaluation of the efficacy of6MWT-Sa02, found that the difference of pre and after-treatment is statistically signific-ant (P<0.01)5. In the Clinical evaluation of chest imaging,36patients after treatment, which improve the9cases, accounting for25%; stable in20cases, accounting for55%; aggravated7cases, accounting for19.4%. The chest imaging improvement is not obvious6. In the Clinical evaluation of the quality of life, I choose the SF-36scale.It’s a Medical Study36-Item Short-Form Health Survey, and is a concise measurement scale developed by the Institute of Health, Boston, USA. In foreign countries, the scale used in clinical studies as a mature quality of life assessment method, there are also reported in the literature that the Chinese version is also suitable for the evaluation of the domestic quality of life of the general population. There is also a study confirmed that the SF-36scale can be used for the efficacy of the evaluation of medical treatment of pulmonary interstitial fibrosis too. And my results of this research show that the quality of life indicators after treatment were significantly elevation (P<0.01), especially in the Role Physical, Bodily Pain, Mental Health.Conclusion:So far, Western medicine on the treatment of pulmonary f ibrosis is still in trouble, but through the research of this subject show that the pulmonary interstitial fibrosis who were treated with the prescription of Yiqihuoxue huatantongluo can improve the clinical symptoms, reducethe patient’s pain, and improve patients’quality of life obviously. The effect is relatively clear, and it is worth to promote in clinical and provid the new clinical basis for Chinese medicine on the prevention of pulmonary interstitial fibrosis.